picaridin: picaridin is the (R,S)-isomer; an insect repellent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 125098 |
| CHEMBL ID | 2104314 |
| CHEBI ID | 143733 |
| SCHEMBL ID | 135432 |
| MeSH ID | M0464174 |
| Synonym |
|---|
| AC-6795 |
| 1-methylpropyl 2-(2-hydroxyethyl)-1-piperidinecarboxylate |
| cutter advanced |
| icaridin [inn] |
| 1-(1-methylpropoxycarbonyl)-2-(2-hydroxyethyl)piperidine |
| icaridina [inn-spanish] |
| 1-methylpropyl 2-(2-hydroxyethyl)piperidine-1-carboxylate |
| icaridine |
| picaridin |
| bayrepel |
| icaridinum [inn-latin] |
| 1-piperidinecarboxylic acid, 2-(2-hydroxyethyl)-, 1-methylpropyl ester |
| icaridina |
| kbr 3023 |
| pikaridin |
| icaridine [inn-french] |
| propidine |
| hsdb 7374 |
| NCGC00163920-01 |
| icaridin |
| 119515-38-7 |
| sec-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate |
| NCGC00163920-02 |
| butan-2-yl 2-(2-hydroxyethyl)piperidine-1-carboxylate |
| AKOS005145519 |
| CHEBI:143733 |
| NCGC00163920-03 |
| tox21_301141 |
| dtxsid0034227 , |
| NCGC00255039-01 |
| cas-119515-38-7 |
| dtxcid8014227 |
| CHEMBL2104314 |
| saltidin |
| sec-butyl 2-(2-hydroxyethyl)piperidine-1- carboxylate/icaridine (icaridine) |
| ccris 8576 |
| unii-n51gqx0837 |
| 2-(2-hydroxyethyl)-1-piperidinecarboxylic acid 1-methylpropyl ester |
| n51gqx0837 , |
| ec 423-210-8 |
| icaridinum |
| icaridin-d3 |
| 2-(2-hydroxyethyl)-1-piperidinecarboxylic acid 1-methyl-d3-propyl ester |
| FT-0602759 |
| icaridin [hsdb] |
| picaridin [mi] |
| hydroxyethyl isobutyl piperidine carboxylate |
| icaridin [mart.] |
| hydroxyethyl isobutyl piperidine carboxylate [inci] |
| icaridin [who-dd] |
| (rs)-sec-butyl (rs)-2-(2-hydroxyethyl)piperidine-1-carboxylate |
| SCHEMBL135432 |
| lcaridin |
| D70300 |
| icaridin (picaridin) |
| QLHULAHOXSSASE-UHFFFAOYSA-N |
| DS-3268 |
| BCP21313 |
| picaridin; kbr 3023; kbr-3023; kbr3023 |
| HY-116144 |
| Q418792 |
| SY111276 |
| mfcd01756488 |
| DB14074 |
| picaridin 100 microg/ml in acetonitrile |
| lcaridinlcaridin |
| CS-0064147 |
| A854464 |
| 119515-38-7 unlabeled |
| 1-(1-methylpropoxycarbonyl)2-(2-hydroxyethyl)piperidine |
| icaridina (inn-spanish) |
| 1-piperidinecarboxylic acid, 2-(2-hydroxyethyl)-2-methylpropyl ester |
| sg plus repellent aroma mist |
| icaridin (mart.) |
| sec-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate/icaridine (icaridine) |
| icaridinum (inn-latin) |
| icaridine (inn-french) |
Picaridin is a new insect repellent that is comparable in effect and less irritating than diethyl toluamide (deet)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Picaridin is a new insect repellent that is comparable in effect and less irritating than diethyl toluamide (deet). " | ( Picaridin: a new insect repellent. Scheinfeld, N, ) | 3.02 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To explore the pharmacokinetic properties of icariin (ICA) and icariside II (ICA II) following intragastric and intravenous administration in rats, a rapid and sensitive method by using ultra-performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) was developed and validated for the simultaneous quantification of ICA and ICA II in rat plasma." | ( Comparative Pharmacokinetics Study of Icariin and Icariside II in Rats. Cheng, T; Ding, Y; Lu, L; Zhang, T; Zhang, Y; Zhao, Y, 2015) | 0.42 |
The maximum concentration in current picaridin formulation is <30%w/v.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Beyond the dosing site, cystic degeneration of the liver was described in 2-year 200-mg KBR 3023/kg body wt/day males." | ( Chronic toxicity and carcinogenicity testing in the Sprague-Dawley rat of a prospective insect repellant (KBR 3023) using the dermal route of exposure. Christenson, WR; Croutch, C; Lake, SG; Sangha, GK; Sheets, LP; Wahle, BS, 1999) | 0.3 |
| " In two experiments using Aedes aegypti, one using a single identical dose and one with varying doses used to develop a dose-response curve, SS220 was as effective as Deet and both compounds were more effective than Bayrepel." | ( Synthesis and repellent efficacy of a new chiral piperidine analog: comparison with Deet and Bayrepel activity in human-volunteer laboratory assays against Aedes aegypti and Anopheles stephensi. Debboun, M; Khrimian, A; Klun, JA; Kramer, M; Margaryan, A, 2003) | 0.32 |
| " According to a logistic regression model fitted to the experimental data, the dose-response relationship for the two repellents was the same within each species, thus pooled ED values were assessed for each mosquito separately." | ( Evaluation of the sensitivity of Aedes aegypti and Anopheles gambiae complex mosquitoes to two insect repellents: DEET and KBR 3023. Badolo, A; Costantini, C; Ilboudo-Sanogo, E; Ouédraogo, AP, 2004) | 0.32 |
| " For each compound, in vitro dose-response assays were conducted with compounds applied to cloth positioned over blood reservoirs covered with Baudruche membrane against Aedes aegypti." | ( A new in vitro bioassay system for discovery of novel human-use mosquito repellents. Debboun, M; Klun, JA; Kramer, M, 2005) | 0.33 |
| " In dose-response tests, the widely used repellents N,N-diethyl-3-methyl benzamide (deet) and 1-methyl-propyl-2-(hydroxyethyl)-1-piperidinecarboxylate (picaridin) were applied to filter paper strips and challenged by ticks at 10, 20, 30, 40, and 120 min after application." | ( Solvent, drying time, and substrate affect the responses of lone star ticks (Acari: Ixodidae) to the repellents deet and picaridin. Bedoukian, RH; Carroll, JF; Kramer, M, 2014) | 0.81 |
| " Averaged for the three compounds, the quantity for the double room was 21-fold higher than for the double cage, which required again a 9-fold higher dosage than the Y-olfactometer." | ( Evaluation of Clove Oil, Icaridin, and Transfluthrin for Spatial Repellent Effects in Three Tests Systems Against the Aedes aegypti (Diptera: Culicidae). Frohberger, S; Nentwig, G; Sonneck, R, 2017) | 0.46 |
| "Applied dosage is one important variable in determining the persistence of a repellent experienced by users but the maximum concentration in current picaridin formulation is <30%w/v." | ( Mosquito repellents for the traveller: does picaridin provide longer protection than DEET? Goodyer, L; Schofield, S, 2018) | 0.94 |
| Class | Description |
|---|---|
| carboxylic acid | A carbon oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid. |
| piperidines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 5.4941 | 0.0002 | 21.2231 | 8,912.5098 | AID743036 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 54.9410 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.35) | 18.2507 |
| 2000's | 34 (40.00) | 29.6817 |
| 2010's | 41 (48.24) | 24.3611 |
| 2020's | 8 (9.41) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (55.44) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (5.49%) | 5.53% |
| Reviews | 9 (9.89%) | 6.00% |
| Case Studies | 2 (2.20%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 75 (82.42%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||